Methionine aminopeptidases: Potential therapeutic target for microsporidia and other microbes
Journal of Eukaryotic Microbiology · 2024-09 · 71 (5)
DOI: 10.1111/jeu.13036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Eukaryotic Microbiology, online erschienen am 22.07.2024. Verfasst von Bhaskar C Das und 6 weiteren Autor:innen. Beteiligte Einrichtung: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Aminopeptidases, Microsporidia, Methionyl Aminopeptidases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Methionine aminopeptidases (MetAPs) have emerged as a target for medicinal chemists in the quest for novel therapeutic agents for treating cancer, obesity, and other disorders. Methionine aminopeptidase is a metalloenzyme with two structurally distinct forms in humans, MetAP‐1 and MetAP‐2. The MetAP2 inhibitor fumagillin, which was used as an amebicide in the 1950s, has been used for the successful treatment of microsporidiosis in humans; however, it is no longer commercially available. Despite significant efforts and investments by many pharmaceutical companies, no new MetAP inhibitors have been approved for the clinic. Several lead compounds have been designed and synthesized by researchers as potential inhibitors of MetAP and evaluated for their potential activity in a wide range of diseases. MetAP inhibitors such as fumagillin, TNP‐470, beloranib, and reversible inhibitors and their analogs guide new prospects for MetAP inhibitor development in the ongoing quest for new pharmacological indications. This perspective provides insights into recent advances related to MetAP, as a potential therapeutic target in drug discovery, bioactive small molecule MetAP2 inhibitors, and data on the role of MetAP‐2 as a therapeutic target for microsporidiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA.
- Department of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA.
- Departments of Pathology and Medicine (Infectious Diseases), Albert Einstein College of Medicine, Bronx, New York, USA.
ORCID-Profile: Bhaskar C Das
Förderung
- NIH HHS
- NIAID NIH HHS
- NIAAA NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Das, B. C., Chokkalingam, P., Shareef, M. A., Shukla, S., Das, S., Saito, M., & Weiss, L. M. (2024). Methionine aminopeptidases: Potential therapeutic target for microsporidia and other microbes. Journal of Eukaryotic Microbiology, 71(5). https://doi.org/10.1111/jeu.13036
Vancouver
Das BC, Chokkalingam P, Shareef MA, Shukla S, Das S, Saito M, et al. Methionine aminopeptidases: Potential therapeutic target for microsporidia and other microbes. Journal of Eukaryotic Microbiology. 2024;71(5). doi:10.1111/jeu.13036
BibTeX
@article{Das2024,
author = {Das, Bhaskar C and Chokkalingam, Parthiban and Shareef, Mohammed Adil and Shukla, Srushti and Das, Sasmita and Saito, Mariko and Weiss, Louis M},
title = {Methionine aminopeptidases: Potential therapeutic target for microsporidia and other microbes},
journal = {Journal of Eukaryotic Microbiology},
year = {2024},
volume = {71},
number = {5},
doi = {10.1111/jeu.13036}
}
EUVIMED